Presentation (CTI)

OBJECTIVES: The main objective of the Canadian Cancer Treatment Hackathon is to improve the Canadian HTA and reimbursement process by engaging diverse perspectives to explore innovative, tailored solutions. The Hackathons aim to: • Identify ways to streamline the drug approval process to ensure Canadian patients receive timely access to cancer drugs • Engage with stakeholders throughout the HTA system to identify process issues and propose solutions. • Provide recommendations to key HTA leaders and organizations to improve time to patient.
METHODS: To explore ways to improve access, Colorectal Cancer Canada held roundtable sessions entitled The Canadian Cancer Treatment Hackathons from November 2022 to March 2025, engaging over 180 thought leaders from Canada and internationally.
RESULTS: The first Hackathon in 2022 focused on novel ideas within existing systems and identified actionable, time-saving opportunities at each step of the HTA process, such as concurrent negotiations alongside HTA reviews. The second examined critical success factors from five leading HTA agencies in England/Wales, France, Germany, Italy, and Australia. The third enabled participants to design a new drug review and reimbursement process, identifying five key themes to improve time to patient. The fourth highlighted high-priority ideas to expedite public access through international collaboration agreements. The fifth identified actionable changes among key stakeholder groups, including patients, industry, and clinicians. The sixth explored improvements at the negotiation level, including earlier integration of patient and caregiver values. The seventh refined tools for collecting and using patient experience data (PED) to ensure meaningful integration of patient voices in drug review and reimbursement The eighth examined outcomes-based agreements (OBAs) to improve access, identifying key success factors for implementation.
CONCLUSIONS: These collaborative efforts demonstrate a strong commitment to improving patient outcomes by advancing Canada’s drug review and reimbursement through strategic partnerships, patient engagement, and adopting international best practices to accelerate access to new cancer treatments.